ĐIỂM BÁO DA LIỀU THÁNG 9/2020



TS.BS. Nguyễn Trọng Hào Ngày 25/9/2020




Dermatologic Clinics



British Journal of Dermatology





Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core


Results From a Prospective, Observational Study

See Editorial by Zayed

BACKGROUND: Lipid-rich necrotic core (LRNC), a high-risk coronary plaque feature assessed by coronary computed tomography angiography, is associated with increased risk of future cardiovascular events in patients with subclinical, nonobstructive coronary artery disease. Psoriasis is a chronic inflammatory condition that is associated with increased prevalence of high-risk coronary plaque and risk of cardiovascular events. This study characterized LRNC in psoriasis and how LRNC modulates in response to biologic therapy.

METHODS: Consecutive biologic naïve psoriasis patients (n=209) underwent coronary computed tomography angiography at baseline and 1-year to assess changes in LRNC using a novel histopathologically validated software (vascuCAP Elucid Bioimaging, Boston, MA) before and after biologic therapy over 1 year.

Harry Choi, MD* Domingo E. Uceda, BS* Amit K. Dey, MD Khaled M. Abdelrahman, Milena Aksentijevich, MSc Justin A. Rodante, PA-C Youssef A. Elnabawi, MD Aarthi Reddy, BS Andrew Keel, RN Julie Erb-Alvarez, MPH Heather Teague, PhD Martin P. Playford, PhD Wunan Zhou, MD, MPH Marcus Y. Chen, MD Joel M. Gelfand, MD, MSCE



	Patients Not Treated With Biologic Therapy, n=85			Patients Treated With Biologic Therapy, n=124			Baseline	1 Year
	Baseline	1 Year	P Value	Baseline	1 Year	P Value	P Value	P Value
Coronary artery charact	terization							
Lipid rich necrotic core								
Max plaque area, mm²	3.12 (1.82 to 4.60)	3.34 (2.04 to 4.74)	0.062	3.12 (1.99 to 4.66)	2.97 (1.84 to 4.35)	0.028*	0.73	0.041*
Δ max plaque area, mm ²		0.14 (-0.84 to 1.37)			-0.22 (-1.17 to 0.87)			0.004*

Table 4. Change in Lipid-Rich Necrotic Core Over 1-Year Between Treatment Groups

	Max Plaque Area					
	Change Over 1	P Value				
Anti-TNF therapy (n=69)	-0.07 (-3.3)					
vs Anti-IL12/23		-0.25 (-8.2)	0.40			
vs Anti-IL17	ļ.,	-0.39 (-14.7)	0.14			
vs NBT		0.19 (5.1)	0.022*			
Anti-IL12/23 (n=26)	-0.25 (-8.2)					
vs Anti-IL17		-0.39 (-14.7)	0.58			
vs NBT		0.19 (5.1)	0.014*			
Anti-IL17 (n=29)	-0.39 (-14.7)	***				
vs NBT		0.19 (5.1)	0.002*			



Buffered lidocaine 1%/epinephrine 1:100,000 with sodium bicarbonate (sodium hydrogen carbonate) in a 3:1 ratio is less painful than a 9:1 ratio: A double-blind, randomized, placebo-controlled, crossover trial

Alexandra Vent, MD, Christian Surber, Dr phil nat, Nicole Tracy Graf Johansen, Dr phil nat, Verena Figueiredo, MSc, Georg Schönbächler, Dr sc nat, Laurence Imhof, MD, Caroline Buset, MD, and Jürg Hafner, MD

Background: Neutralizing (buffering) lidocaine 1%/epinephrine 1:100,000 solution (Lido/Epi) with sodium hydrogen carbonate (NaHCO₃) (also called sodium bicarbonate) is widely used to reduce burning sensations during infiltration of Lido/Epi. Optimal mixing ratios have not been systematically investigated.

Objectives: To determine whether a Lido/Epi:NaHCO₃ mixing ratio of 3:1 (investigational medicinal product 1) causes less pain during infiltration than a mixing ratio of 9:1 (IMP2) or unbuffered Lido/Epi (IMP3).

Methods: Double-blind, randomized, placebo-controlled, crossover trial ($n = 2 \times 24$) with 4 investigational medicinal products (IMP1-4).

Lidocaine

- Concentrations: 0.5%-2.5%; 1% most commonly used.
- Epinephrine added 1:100,000
- lidocaine products with or without epinephrine: pH = 2.5 -4.0
- sodium hydrogen carbonate (NaHCO3) 8.4% added (10:1 to 5:1)

Group 2 Group 2

IMP 1

1 vial (5ml) with Lido/Epi 15mg/ml, 15μg/ml 1 vial (5ml) with NaHCO₃ 42mg/ml

> mixed, resulting in 10ml

 $Lido/Epi-NaHCO_3 = 3:1 (pH 7.5)$

containing

Lido 7.5mg/ml, NaHCO₃ 21mg/ml

set

IMP 2

1 vial (5ml) with Lido/Epi 18mg/ml, 18μg/ml 1 vial (5ml) with NaHCO₃ 16.8mg/ml > mixed, resulting in 10ml

Lido/Epi-NaHCO₂ = 9:1 (pH 7.3)

containing

Lido 9mg/ml, NaHCO₃ 8.4mg/ml

set

kit

IMP 1

1 vial (5ml) with Lido/Epi 15mg/ml, 15μg/ml

1 vial (5ml) with NaHCO₃ 42mg/ml > mixed, resulting in 10ml

 $Lido/Epi-NaHCO_3 = 3:1 (pH 7.5)$

containing

Lido 7.5mg/ml, NaHCO₃ 21mg/ml

set

IMP₃

1 vial (5ml) with Lido/Epi 10mg/ml, 10μg/ml 1 vial (5ml) with Lido/Epi 10mg/ml, 10μg/ml > mixed, resulting in 10ml

Lido (pH 3.8)

containing Lido 10mg/ml

set

IMP 2

1 vial (5ml) with Lido/Epi 18mg/ml, 18µg/ml

1 vial (5ml) with NaHCO₃ 16.8mg/ml

> mixed, resulting in 10ml

 $Lido/Epi-NaHCO_3 = 9:1 (pH 7.3)$

containing

Lido 9mg/ml, NaHCO₃ 8.4mg/ml

set

IMP 4 (placebo)

1 vial (5ml) with NaCl 0.9%

1 vial (5ml) with NaCl 0.9%

> mixed, resulting in 10ml

NaCl 0.9% (pH 6.3)

containing NaCl 0.9mg/ml

set


kit

IMP 1 vs IMP 2

- n = 24, block randomization in 4 blocks (n = 6)
- Each participant receives 1 encoded kit containing 2 encoded sets, each set containing 2 blinded vials
- Infiltration of 2ml IMP per site (8ml discarded)
- 12 participants start with IMP 1 and 12 with IMP 2

IMP 1 vs IMP 2 vs IMP 3 vs IMP 4 (placebo)

- n = 24, block randomization in 1 block (n = 24)
- Each participant receives 1 encoded kit containing 4 encoded sets, each set contains 2 blinded vials
- Each participant receives the 4 IMPs in a different order (24 possibilities).
- Infiltration of 2ml IMP per site (3cm wheal) (8ml discarded)



Treatment of periocular and temporal reticular veins with 1064-nm Nd:YAG Laser

Tee Sin Lee MBBS, MRCS, MMED, FAMS^{1,2} |

James Wei Ming Kwek MBBS, DWD(CAW), MRCS, MMED¹

David A. F. Ellis MD, FRCSC, FACS²

¹Department of Otolaryngology Head and Neck Surgery, Changi General Hospital, Singapore City, Singapore

²Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology–Head and Neck Surgery, University of Toronto, Toronto, ON, Canada

Correspondence

Tee Sin Lee, Department of Otolaryngology Head and Neck Surgery, Changi General Hospital, 2 Simei Street 3, Singapore City 529889, Singapore.


Email: leeteesin@gmail.com

Abstract

Background: The periocular and temporal regions are important aspects of beauty. The presence of reticular veins in these areas is undesirable and can also interfere with injection of neurotoxins to treat squint lines. 1064-nm Nd:YAG laser shows promise as an effective treatment modality with long-lasting effects.

Aim: The aim of the study is to show that the long-pulsed, contact-cooled, variable spot-sized 1064-nm Nd:YAG laser is effective and safe, with good patient satisfaction and tolerability, and is able to achieve long-term results.

Methods: A retrospective study of 35 consecutive patients seen over a 3-year period in a private cosmetic clinic affiliated to the University of Toronto for periocular and temporal reticular veins was conducted. They were all treated with 1064-nm Nd:YAG laser.





Lee TS et al. J Cosmet Dermatol. 2020;19:2306–2312



Lee TS et al. J Cosmet Dermatol. 2020;19:2306–2312

Disposable syringe punching: An aseptic alternative to a comedo extractor




Jun Young Kim, MD Daegu, South Korea

CLINICAL CHALLENGE

Generally, dermatologists extract comedones by using a clean comedo extractor in their clinic, but comedo extractors are sometimes not available. The comedones can be squeezed out directly with fingernails or extracted by using alternatives such as pen punching, safety pins, or versatile paper clips^{1,2}; however, these alternatives are hard to find and have contamination issues.

SOLUTION

Common aseptic disposable syringes are an option for comedo extraction (Fig 1, A). The diameter of the tip of a needleless syringe is approximately 2 mm (Fig 1, B). The lesions should be prepped with alcohol (Fig 1, C), and light to medium pressure should be applied directly on top of the lesion with the tip of a needleless syringe (Fig 1, D) until all of the material is exposed (Fig 1, E, E). If the lesion is a closed comedo, a tiny prick incision with the removed beveled needle can be used to slightly pierce the epidermis. Although the patient may feel minor discomfort as a result of pressure, complaints of pain can prompt the physician to stop and retry the technique. The advantages of this technique include the availability of syringes in any clinic and the use of a disposable aseptic syringe that allows the procedure to be conducted aseptically. In addition, there is no need for a scalpel when making prick incisions and no chance for injury because the margin of the syringe tip is blunt, and the 1-cm protruding tip of the syringe can reach concave and deep areas. This technique is useful and easy.



Kim JY. J Am Acad Dermatol 2020;83:e175-6





Neha Taneja, MD, Sanjeev Gupta, MD, and Somesh Gupta, MD

New Delbi and Mullana, India


Key words: cryotherapy; precision; template.

SURGICAL CHALLENGE

Cryotherapy in dermatology, though effective, is limited by its side effects, a significant one being the lateral spread of cryogen on to the surrounding normal-appearing skin. To minimize runoff, neoprene and otoscope cones have been used, but these are expensive and available only in the shape of a circle with a limited range of sizes. The skin lesions requiring cryotherapy do not always conform to these fixed geometric dimensions and, therefore, lead to imprecise treatment areas.

SOLUTION

We propose the use of thin, flexible polyurethane cryoshield templates, either prefenestrated in various shapes and sizes (prefenestrated template [PFT]) or cut-out identical to the dimensions of the lesion (disposable customizable template [DCT]) to prevent peripheral spread of the cryogen. PFTs are reusable (can be wiped with antiseptic solution and reused), and DCTs are disposed after use.



Precise freezing in cryotherapy using customized and pre-designed templates with holes of diverse sizes and shapes

Neha Taneja, Sanjeev Gupta, Somesh Gupta

Department of Dermatology and Venereology All India Institute of Medical Sciences, New Delhi, India Precise freezing in cryotherapy using customized and pre-designed templates with holes of diverse sizes and shapes

Neha Taneja, Sanjeev Gupta, Somesh Gupta

Department of Dermatology and Venereology All India Institute of Medical Sciences, New Delhi, India

Trap technique for bloodless removal of digital pyogenic granuloma



Deepak Jakhar, MD,^a and Ishmeet Kaur, MD^b New Delbi, India

Key words: lobular capillary hemagioma; Penrose drain; pyogenic granuloma; surgical removal; tourniquet.

SURGICAL CHALLENGE

Pyogenic granuloma (PG) is a lobular capillary hemangioma. Owing to their vascular nature, PGs have a high tendency to bleed during surgical removal. PG at highly vascular sites such as the digits further complicates the issue. A bloodless surgical field is required to assist in complete removal of PG to prevent recurrence.

SOLUTION

A Penrose drain is frequently used as a tourniquet to achieve hemostasis. The same tourniquet can be used during surgical removal of PG (Fig 1, A). After digital block anesthesia has been administered, the tourniquet is



Jakhar D et al. J Am Acad Dermatol 2020;83:e109-10

Two-step, imaging-device—guided, precise filler-injection technique



Yau-Li Huang, MD, a,b Shyue-Luen Chang, MD, a,b and Chun-Yu Cheng, MD Taoyuan, Taiwan

Key words: filler injection; ultrasound; vein finder.


SURGICAL CHALLENGE

Hyaluronic acid injection is one of the most common procedures for facial rejuvenation and volumization. Although it is generally considered safe, complications sometimes occur, such as bruising, cutaneous necrosis, and blindness. Although knowledge of facial anatomy may minimize the risk, the distribution of vessels varies for each patient.


SOLUTION

We used Vein Viewer (Christie Medical Holdings, Inc, Memphis, TN) and ultrasonography (Acuson X150, Siemens Medical Solutions USA, Mountain View, CA) to assist with filler injection. In the first step, we applied the Vein Viewer to detect superficial vein distribution over the treated area and to choose the entry point without venipuncture (Fig 1, A). In the second step, we performed ultrasonography with color Doppler to detect sequential deep anatomic structures and guide the pathway of the filler injection to prevent intravascular infusion (Fig 1, B-E).

Vein Viewer is a device that uses near-infrared light to illuminate the patient's skin. The near-infrared light penetrates the skin and subcutis with low absorption. In contrast, near-infrared light is absorbed by blood, causing dark shadows. Therefore, it can show the superficial vasculature and help us choose an entry point to prevent venipuncture and bruising. The ultrasonography and color Doppler provide us real-time images of the location of blood vessels and anatomic structures in the treated area. Hence, we can inject filler in the correct anatomic layer and avoid intravascular infusion. Under the guidance of both devices, we can perform filler injection more delicately and reduce the risk of complications.



Huang Y et al. J Am Acad Dermatol 2020;83:e119-20





Ultrasound-guided median and ulnar nerve blocks in the forearm to facilitate onabotulinum toxin A injection for palmar hyperhidrosis


Arun Kalava, MD, FASA, EDRA, and Briana C. Colon, BS Tampa, Florida


Key words: hyperhidrosis; median nerve; nerve block; onabotulinum toxin A; ulnar nerve; ultrasound.

THERAPEUTIC CHALLENGE

Onabotulinum toxin A injections are used to treat palmar hyperhidrosis and often result in intolerable pain when multiple injections are administered. Cold packs, local anesthetic, ethyl chloride spray, and anesthetic cream are not effective modalities to minimize the pain of the injections.

Performing median and ulnar nerve blocks before onabotulinum toxin A injections are an excellent technique to reduce pain but have the risk of nerve injury and mechanical damage when performed without imaging. We propose ultrasound-guided median (Fig 1) and ulnar nerve (Fig 2) blocks in the forearm to reduce the risk of mechanical and neural damage.





Kalava A et al. J Am Acad Dermatol 2020;83:e277-8

Burning Mouth Syndrome



Brittany Klein, DDS^a, Jaisri R. Thoppay, DDS, MBA, MS^b, Scott S. De Rossi, DMD, MBA^c, Katharine Ciarrocca, DMD, MSEd^{d,*}

KEYWORDS

Oral burning
 Dry mouth
 Glossodynia
 Burning mouth syndrome
 Oral dysesthesia

KEY POINTS

- Burning mouth syndrome (BMS) is a chronic condition characterized by a burning sensation of the intraoral mucosa in the absence of a local or systemic cause.
- A diagnosis of BMS should be made only after a thorough history, clinical examination, and indicated laboratory studies have ruled out local or systemic cause.
- Despite advances in the understanding and treatment of BMS, it remains a challenging condition for both patients and providers.
- Some patients experience at least partial remission of symptoms with or without treatment, but, for many, symptoms persist. Management should be aimed at symptom reduction and coping strategies.

Type 1 Morning Day Evening Symptom-free • Peak waking sensation progresses in Burning sensation develops late throughout morning Type 2 Morning Day Evening Continuous burning symptoms Type 3 Intermittent symptoms present only some days

Klein B et al. Dermatol Clin 38 (2020) 477-483

Local factors

- Poorly fitting dentures
- Parafunctional habits
 - Candidiasis
- Oral mucosal diseases
- Local allergic reaction

Systemic factors

- Nutritional deficiencies –
 Vitamin B12, B6, iron, zinc
- Endocrine disorders –
 Diabetes mellitus, thyroid disease, hormonal deficiencies
 - Hyposalivation
- Medication side effect
- Upper respiratory tract infection
- Gastroesophageal reflex disease

Psychologic Factors

- Depression
 - Anxiety

Chief complaint and history of present illness

- · Oral burning,
- +/- Xerostomia
- +/- Dysguesia
- Duration and intensity
- Pattern and frequency
- Localization
- Symptom onset and progress
- Aggravating and reliving factors
- +/- Prior history of episodes
- Impact on functions
- +/- Parafunctional oral habits
- +/- Jaw muscle pain
- Last dental visit

Medical and surgical history

- Metabolic and endocrine disorders [Diabetes, Thyroid disease]
- Autoimmune disease
- Pervious upper respiratory tract infections
- Psychiatric disorders
 - Nutritional deficiencies
- Medication history
 - GERD
 - Allergies
- History of chemotherapy or radiation therapy in orofacial area

Clinical exam and recommended tests

- Extraoral and intraoral exam
- Sialometry if hyposalivation is suspected
- Culture oral samples for fungal infection if candidiasis is suspected and empiric therapy fails

Recommended laboratory studies

- Complete blood cell count with differential
 - Fasting blood glucose
- Serum iron, Ferritin
- Vitamin B6, vitamin B12, and vitamin D

Category	Medication	Topical or Systemic	Dose and Delivery			
Benzodiazepine	Clonazepam	Topical	0.5 mg to 2 mg swish and expectorate or tablet held in mouth and expectorated			
		Systemic	0.5 mg capsule or orally disintegrating tablet starting dose taken at bedtime, not to exceed 2mg/d			
Tricyclic antidepressant	Amitriptyline	Systemic	10–25-mg starting dose taken at bedtime, titrated to maximum dose of 100–125 mg			
Anticonvulsant	Gabapentin	Systemic	300 mg/d at bedtime starting dose, up to 900–1200 mg 3 times daily			
Atypical analgesic	Capsaicin	Topical	0.2% solution (can dilute Tabasco™ sauce) swish and expectorate 4 times daily			
Supplement	Alpha-lipoic acid	Systemic	200 mg 3 times daily			

GUIDELINES

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

```
P. Joly, <sup>1,*</sup> D. B. Horvath, <sup>2</sup> A Patsatsi, <sup>3</sup> S. Uzun, <sup>4</sup> D. R. Bech, <sup>5</sup> S. Beissert, <sup>6</sup> R. Bergman, <sup>7</sup> P. Bernard, <sup>8</sup> L. Borradori, <sup>9</sup> D. M. Caproni, <sup>10</sup> F. Caux, <sup>11</sup> G. Cianchini, <sup>12</sup> D. M. Daneshpazhooh, <sup>13</sup> D. De, <sup>14</sup> D. M. Dmochowski, <sup>15</sup> D. K. Drenovska, <sup>16</sup> D. J. Ehrchen, <sup>17</sup> C. Feliciani, <sup>18</sup> D. M. Goebeler, <sup>19</sup> D. R. Groves, <sup>20</sup> D. C. Guenther, <sup>21</sup> D. S. Hofmann, <sup>22</sup> D. Ioannides, <sup>23</sup> C. Kowalewski, <sup>24</sup> R. Ludwig, <sup>25</sup> D. Y.L. Lim, <sup>26</sup> B. Marinovic, <sup>27</sup> A.V. Marzano, <sup>28,29</sup> D. J.M. Mascaró Jr, <sup>30</sup> D. Mimouni, <sup>31</sup> D. F. Murrell, <sup>32</sup> D. C. Pincelli, <sup>33</sup> D. C.P. Squarcioni, <sup>34</sup> M. Sárdy, <sup>35</sup> J. Setterfield, <sup>36</sup> D. E. Sprecher, <sup>37,38</sup> D. S. Vassileva, <sup>39</sup> D. K. Wozniak, <sup>40</sup> S. Yayli, <sup>41</sup> D. G. Zambruno, <sup>42</sup> D. Zillikens, <sup>43</sup> M. Hertl, <sup>44</sup> D. E. Schmidt <sup>43</sup> D.
```


Mild pemphigus foliaceus* 1st line treatment Dapsone: start dose 50 to 100 mg/day, up to 1.5 mg/kg body weight, usually combined with topical corticosteroids · Topical corticosteroids: (class III, IV) alone if there are only very limited lesions Systemic corticosteroids: prednisone 0.5-1.0 mg/kg/day Rituximab: two infusions of 1g two weeks apart, alone, or associated with topical corticosteroids or oral prednisone 0.5 mg/kg/day 2nd line treatment · Rituximab: two infusions of 1g two weeks apart, alone, or associated with topical corticosteroids or oral prednisone 0,5 mg/ kg/day, in patients previously treated with dapsone or topical corticosteroids · Systemic corticosteroids: prednisone 0.5-1.0 mg/kg/day with or without azathioprine (1 to 2.5 mg/kg/d), or mycophenolate mofetil 2g/day or mycophenolate sodium 1440 mg/d - if rituximab is not available or contraindicated Disease control No achieved Yes Disease control achieved Disease control not achieved Continue previous treatment · Add Rituximab · Dapsone 1.5mg/kg/day Add prednisone 0.5-1.0 mg/kg/day And/or or Prednisolone azathioprine (1 to 2.5 mg/kg/d) mycophenolate mofetil 2g/day · Topical corticosteroids mycophenolate sodium 1440 mg/d

Treatment algorithm for mild pemphigus foliaceus. *involved body surface area < 5 % and/or PDAI score ≤ 15.

Mild pemphigus vulgaris* 1st line treatment · Rituximab: two infusions of 1g two weeks apart, alone, or associated with oral prednisone 0.5 mg/kg/day with a rapid decrease in order to stop corticosteroids after 3 or 4 months Systemic corticosteroids: prednisone 0.5-1.0 mg/kg/day with or without azathioprine (2.0 mg/kg/d), or mycophenolate mofetil 2 g/day or mycophenolate sodium 1440 mg/d Disease control achieved 2nd line treatment = disease control not achieved or cs side effects or ci to conventional immunosupppressants Continue previous treatment with rapid decrease in order to stop · Patients initially treated with prednisone/ prednisolone corticosteroids after 3 or 4 months (if 0.5-1.0 mg/kg/day alone: Add rituximab (two infusions of 1g two combined with rituximab), or slower weeks apart) with a rapid decrease of oral prednisolone in order without rituximab to stop corticosteroids after 3 or 4 months Patients initially treated with prednisone/ prednisolone 0.5-1.0 mg/kg/day plus rituximab: increase the dose of prednisone up to 1 mg/kg/day

Figure 2 Treatment algorithm for mild pemphigus vulgaris. *involved body surface area < 5 % and/or limited oral lesions not impairing food intake or requiring analgesics and/or PDAI score ≤ 15.

Moderate to severe PV/PF



Treatment algorithm for moderate and severe pemphigus vulgaris and pemphigus foliaceus. CR, complete remission

Summary

- Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core
- 2. Buffered lidocaine 1%/epinephrine 1:100,000 with sodium bicarbonate (sodium hydrogen carbonate) in a 3:1 ratio is less painful than a 9:1 ratio: A double-blind, randomized, placebo-controlled, crossover trial
- 3. Treatment of periocular and temporal reticular veins with 1064-nm Nd:YAG Laser
- 4. Disposable syringe punching: An aseptic alternative to a comedo extractor
- 5. High-precision freezing in cryotherapy by using customized and predesigned templates
- 6. Trap technique for bloodless removal of digital pyogenic granuloma
- 7. Two-step, imaging-deviceeguided, precise filler-injection technique
- 8. Ultrasound-guided median and ulnar nerve blocks in the forearm to facilitate onabotulinum toxin A injection for palmar hyperhidrosis
- 9. Burning Mouth Syndrome
- 10. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)



Chủ đề Điều trị kết hợp trong thẩm mỹ nội khoa

Thời gian: Thứ bảy, ngày 17/10/2020

Địa điểm: BV Da Liễu Tp.HCM

HỘI NGHỊ KHOA HỌC DA LIỀU MIỀN NAM

"Những thách thức hiện nay trong chuyên ngành Da Liễu"

Thời gian: Chủ nhật, ngày 18/10/2020

Địa điểm: GEM Center, Q1, TP.HCM